126 related articles for article (PubMed ID: 2491884)
1. Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.
Wadler S; Egorin MJ; Zuhowski EG; Tortorello L; Salva K; Runowicz CD; Wiernik PH
J Clin Oncol; 1989 Jan; 7(1):132-9. PubMed ID: 2491884
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
5. Phase I/pharmacokinetic reevaluation of thioTEPA.
O'Dwyer PJ; LaCreta F; Engstrom PF; Peter R; Tartaglia L; Cole D; Litwin S; DeVito J; Poplack D; DeLap RJ
Cancer Res; 1991 Jun; 51(12):3171-6. PubMed ID: 1710167
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer.
Lewis C; Lawson N; Rankin EM; Morrison G; MacLean AB; Cordiner J; Cassidy J; Kerr DJ; Kaye SB
Cancer Chemother Pharmacol; 1990; 26(4):283-7. PubMed ID: 1695127
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.
Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J
Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
O'Dwyer PJ; LaCreta FP; Schilder R; Nash S; McAleer C; Miller LL; Hudes GR; Ozols RF
J Clin Oncol; 1992 Aug; 10(8):1352-8. PubMed ID: 1634926
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
[TBL] [Abstract][Full Text] [Related]
11. Dosing of thioTEPA for myeloablative therapy.
Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
[TBL] [Abstract][Full Text] [Related]
12. High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.
Wolff SN; Herzig RH; Fay JW; LeMaistre CF; Brown RA; Frei-Lahr D; Stranjord S; Giannone L; Coccia P; Weick JL
Semin Oncol; 1990 Feb; 17(1 Suppl 3):2-6. PubMed ID: 2106165
[TBL] [Abstract][Full Text] [Related]
13. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
Ackland SP; Choi KE; Ratain MJ; Egorin MJ; Williams SF; Sinkule JA; Bitran JD
J Clin Oncol; 1988 Jul; 6(7):1192-6. PubMed ID: 3134519
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer.
Shapiro CL; Dezube BJ; Tretyakov O; Wright J; Cap B; Henderson IC; Hayes DF
Clin Cancer Res; 1995 Aug; 1(8):791-6. PubMed ID: 9816047
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intraperitoneal mitomycin C.
van Ruth S; Verwaal VJ; Zoetmulder FA
Surg Oncol Clin N Am; 2003 Jul; 12(3):771-80. PubMed ID: 14567030
[TBL] [Abstract][Full Text] [Related]
16. A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
van Maanen MJ; Tijhof IM; Damen JM; Versluis C; van den Bosch JJ; Heck AJ; Rodenhuis S; Beijnen JH
Cancer Res; 1999 Sep; 59(18):4720-4. PubMed ID: 10493531
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intraventricular and intravenous N,N',N''-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans.
Strong JM; Collins JM; Lester C; Poplack DG
Cancer Res; 1986 Dec; 46(12 Pt 1):6101-4. PubMed ID: 3096555
[TBL] [Abstract][Full Text] [Related]
18. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
19. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
20. Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.
Zimm S; Cleary SM; Horton CN; Howell SB
J Clin Oncol; 1988 Apr; 6(4):696-700. PubMed ID: 3357007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
